76
|
Felip E, Van Meerbeeck J, Wolf J, Ardizzoni A, Li A, Srinivasan S, Popat S. 193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30302-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
77
|
Deodato F, Cilla S, Morganti A, Annese C, Macchia G, Ianiro A, Picardi V, Digesù C, Ferro M, Labropoulos F, Torre G, Nuzzo M, Dinapoli N, Valentini V, Veraldi A, Zanirato A, Romani F, Zompatori M, Cammelli S, Ardizzoni A, Frezza G. EP-1206: Adequacy of dose/volume constraints in stereotactic radiotherapy and radiosurgery of thoracic area. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32456-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
78
|
Picardi V, Macchia G, Cilla S, Di Bartolomeo M, Giordano M, Rotondi F, Gambacorta M, Deodato F, Ronchi L, Farioli A, Guido A, Siepe G, Compagnone G, Ardizzoni A, Cammelli S, Frezza G, Valentini V, Morganti A. PO-0716: Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study (Grace-Rectum-1). Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31966-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
79
|
Giordani S, Teneggi C, D'Amico S, Nicoletti G, Pandolfi P, Ardizzoni A. An innovative program of integrative rehabilitation based on promoting healthy lifestyles for cancer survivors. Preliminary results of an experimental study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
80
|
Morabito A, Brandes A, Sibau A, Ciuffreda L, Favaretto A, Cappuzzo F, Santoro A, Vasile E, Brighenti M, Ferraù F, Giordano P, Tiseo M, Soria J, Felip E, Lu S, Goss G, Gadgeel S, Georgoulias V, Chand V, Ardizzoni A. Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
81
|
Del Re M, Tiseo M, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Bordi P, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
82
|
Martoni A, Melotti B, Degli Esposti C, Lelli G, Mutri V, Corrado D, Ansaloni S, Pannuti F, Strocchi E, Ardizzoni A. Integration of medical oncology and palliative care to improve the appropriateness of antitumor therapy near the end of life in advanced cancer patients: first evidences of the prospective sequential MIRTO study. (Supported by “Programma di Ricerca Regione Emilia-Romagna-Università 2007-2009 Area 2 - Ricerca per il Governo clinico”). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
83
|
Ardizzoni A, Posteraro B, Baschieri MC, Bugli F, Sáez-Rosòn A, Manca L, Cacaci M, Paroni Sterbini F, De Waure C, Sevilla MJ, Peppoloni S, Sanguinetti M, Moragues MD, Blasi E. An antibody reactivity-based assay for diagnosis of invasive candidiasis using protein array. Int J Immunopathol Pharmacol 2014; 27:403-12. [PMID: 25280031 DOI: 10.1177/039463201402700310] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The increased incidence of invasive candidiasis and of patients at risk requires early diagnosis and treatment to improve prognosis and survival. The aim of this study was to set up a ten-protein array-based immunoassay to assess the IgG antibody responses against ten well-known immunogenic C. albicans proteins (Bgl2, Eno1, Pgk1, Pdc11, Fba1, Adh1, Als3, Hwp1, Hsp90 and Grp2) in 51 patients with invasive candidiasis (IC) and in 38 culture-negative controls (non-IC). Antibody levels were higher against Bgl2, Eno1, Pgk1, Als3, Hwp1 and Grp2, than against Adh1, Pdc11, Fba1 and Hsp90, irrespectively of the patient group considered. Moreover, the IgG levels against Bgl2, Eno1, Pgk1 and Grp2 were significantly higher in IC than in non-IC patients. Furthermore, the ROC curves generated by the analysis of the antibody responses against Bgl2, Grp2 and Pgk1 displayed AUC values above 0.7, thus discriminating IC and non-IC patients. According to these results, the employment of the microarray immunoassay (a rapid, sensitive and multiparametric system), in parallel with conventional diagnostics, can help to spot IC patients. This ultimately will allow to initiate an early, focused and optimized antifungal therapy.
Collapse
|
84
|
Orsi CF, Sabia C, Ardizzoni A, Colombari B, Neglia RG, Peppoloni S, Morace G, Blasi E. Inhibitory effects of different lactobacilli on Candida albicans hyphal formation and biofilm development. J BIOL REG HOMEOS AG 2014; 28:743-752. [PMID: 25620183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The aim of this study was to investigate the effects of different species of Lactobacilli on hyphal formation and biofilm development by the opportunistic fungal pathogen Candida albicans. We employed 4 different Lactobacillus species, namely L. rhamnosus, L. acidophilus, L. plantarum and L. reuteri, and 2 C. albicans strains, the reference DAY286 and its isogenic hwp1/hwp1 mutant, the FJS24 strain. As assessed by morphological analysis and quantitative colorimetric assays, Lactobacillus crude filtrate supernatant fluids (CFSF) affected Candida, impairing both hyphal formation and biofilm production. The CFSF-mediated phenomenon occurred in a dilution- and time-dependent manner and was consistently observed, irrespective of the C. albicans HWP1 genotype.
Collapse
|
85
|
Goss G, Felip E, Cobo M, Lu S, Syrigos K, Lee K, Göker E, Georgoulias V, Li W, Isla D, Morabito A, Guclu S, Min Y, Ardizzoni A, Gadgeel S, Love J, Chand V, Soria JC. A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
86
|
Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2014; 21:1-16. [PMID: 24344249 DOI: 10.1530/erc-13-0246] [Citation(s) in RCA: 166] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neuroendocrine neoplasms is based on Ki67 proliferation assessment and proved prognostically effective. This study aims at comparing these two classifications and at defining a prognostic grading system for lung neuroendocrine tumors. The study included 399 patients who underwent surgery and with at least 1 year follow-up between 1989 and 2011. Data on 21 variables were collected, and performance of grading systems and their components was compared by Cox regression and multivariable analyses. All statistical tests were two-sided. At Cox analysis, WHO 2004 stratified patients into three major groups with statistically significant survival difference (typical carcinoid vs atypical carcinoid (AC), P=0.021; AC vs large-cell/small-cell lung neuroendocrine carcinomas, P<0.001). Optimal discrimination in three groups was observed by Ki67% (Ki67% cutoffs: G1 <4, G2 4-<25, G3 ≥25; G1 vs G2, P=0.021; and G2 vs G3, P≤0.001), mitotic count (G1 ≤2, G2 >2-47, G3 >47; G1 vs G2, P≤0.001; and G2 vs G3, P≤0.001), and presence of necrosis (G1 absent, G2 <10% of sample, G3 >10% of sample; G1 vs G2, P≤0.001; and G2 vs G3, P≤0.001) at uni and multivariable analyses. The combination of these three variables resulted in a simple and effective grading system. A three-tiers grading system based on Ki67 index, mitotic count, and necrosis with cutoffs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate.
Collapse
|
87
|
Ardizzoni A, Tiseo M. Second-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC). J Chemother 2013; 16 Suppl 4:104-7. [PMID: 15688623 DOI: 10.1179/joc.2004.16.supplement-1.104] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
An increasing number of patients with advanced non-small cell lung cancer (NSCLC) progressing after front-line chemotherapy are still in good performance status and willing to receive further treatment. Several drugs have been tested in this setting of treatment, but the only agent registered world-wide for second-line chemotherapy of advanced NSCLC is docetaxel. This drug, at dose of 75 mg/m2 every three weeks, has been the standard of care as second-line chemotherapy since 2000, based on two trials that reported improved survival times and quality of life when comparing with best supportive care (TAX 317) and with ifosfamide or vinorelbine (TAX 320). Docetaxel, given at this dose and schedule, resulted in significant haematological toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. In a phase III study in 571 patients pemetrexed, comparing with docetaxel in second-line chemotherapy, demonstrated clinically equivalent therapeutic outcomes, but a more favourable haematological toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Others several agents have been evaluated for the second-line treatment of patients with non-small cell lung cancer, but no comparative phase III studies with docetaxel has been carried out. The epidermal growth factor receptor-tyrosine kinase inhibitors gefitinib (ZD1839, Iressa) and erlotinib (OSI 774, Tarceva) have been evaluated in the second- and third-line setting. Both drugs have demonstrated interesting response rates and toxicity profile and, in particular, erlotinib evidenced a survival advantage of 2 months respect placebo in recent phase III trial. Future developments are likely to value poli-chemotherapy or combination chemotherapy with EGFR tyrosine kinase inhibitors in second-line treatment of advanced NSCLC.
Collapse
|
88
|
Bozzetti C, Passaro A, Cavazzoni A, Carubbi C, Lagrasta C, Quaini F, Nicolazzo C, Gnetti L, Ardizzoni A, Tiseo M. 2PD ISOLATION AND CHARACTERIZATION OF CIRCULATING TUMOR CELLS IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE LUNG. Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70224-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
89
|
Loprevite M, Varesco L, Favoni R, Ferrara G, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi M, Pozzi S, Pera C, Biticchi R, Gismondi V, Grossi F, Pennucci M, Ardizzoni A. Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. Int J Oncol 2012; 11:1203-8. [PMID: 21528323 DOI: 10.3892/ijo.11.6.1203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Six non-small cell lung cancer (NSCLC) cell lines (A-549, Ca-Lu-6, SK-Lu-1, Ca-Lu-1, SK-Mes-1 and LX-1) were studied to assess the presence of multiple concomitant alterations of different oncogenes (K-ras, bcl-2) and tumor suppressor genes (p53, Rb) in NSCLC. K-ras (exon 1) and p53 (exons 5-8) gene mutations were determined via a PCR-based-DGGE (Denaturing Gradient Gel Electro-phoresis) and by sequencing approach. Different mutations were found in the Ist exon of K-ras gene in 5 of 6 cell lines examined. Five of six cell lines contained K-ras mutations at codon 12 (A-549, SK-Lu-1, LX-1) or codon 13 (SK-Mes-1, Ca-Lu-1). In addition, 5 of 6 cell lines showed p53 mutations of exon 8 (SK-Mes-1, Ca-Lu-1 cod. 280; LX-1 cod. 273) or exon 6 (Ca-Lu-6 cod. 196; SK-Lu-1 cod. 193). In 4 of these cell lines, p53 protein nuclear expression was also confirmed with DO-7 mAb immunocytochemistry. Expression of cytoplasmic bcl-2 protein, by anti-bcl-2 mAb flow cytometric analysis, was found in A-549, Ca-Lu-1, SK-Lu-1, SK-Mes-1 cell lines. In contrast, RT-PCR analysis of Rb gene could not identify any change in the cell lines examined. In conclusion, most NSCLC cell lines tested displayed concomitant multiple oncogene/tumor suppressor gene alterations.
Collapse
|
90
|
La Sala G, Ardizzoni A, Capodanno F, Manca L, Baschieri M, Soncini E, Peppoloni S, Blasi E. Protein Microarrays and Midtrimester Amniotic Fluids: A Novel Approach for the Diagnosis of Early Intrauterine Inflammation Related to Preterm Delivery. Int J Immunopathol Pharmacol 2012; 25:1029-40. [DOI: 10.1177/039463201202500420] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Novel technologies that allow simultaneous assessment of multiple biomarkers provide new and promising diagnostic/prognostic approaches. By protein microarrays, here we analyzed amniotic fluids (AF) from 50 women with preterm delivery (PTD) and 50 control women, who delivered at term. In detail, cytokines, chemokines, matrix metalloproteinases and antigen-specific antibodies were assessed. The AF analysis showed significant differences between women with preterm and term delivery in the levels of IL-1α, IL-1β, IL-4, IL-6, IL-8, MCP-1, IFN-γ and anti-HSV2 IgG. No significant differences were observed in the levels of TNF-α, MMP-2, MMP-9 and specific IgG for seven vertically transmitted pathogens. In conclusion, we demonstrated the feasibility of protein microarrays in the diagnosis of early intrauterine inflammation. The significant association between the increased levels of certain cytokines and preterm delivery argues on their relevance as early pathogenetic markers for identification of risk patients.
Collapse
|
91
|
Goss G, Lu S, Felip E, Ardizzoni A, Georgoulias V, Gadgeel S, Chand V, Gu Y, Olivo Y, Soria J. Lux-Lung 8: A Randomized, Open-Label, Phase III Trial of Afatinib vs. Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung as Second-Line Therapy Following First-Line Platinum-Based Chemotherapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33072-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
92
|
Buti S, Bordi P, Tiseo M, Panni S, Novello S, Bria E, Rapetti S, Pilotto S, Camisa R, Ardizzoni A. Erythrocyte Mean Corpuscular Volume Change During Pemetrexed Treatment in Advanced Non Small Cell Lung Cancer Patients. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33818-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
93
|
Musolino A, Bella M, Michiara M, Zanelli P, Naldi N, Bortesi B, Sgargi P, Camisa R, Neri T, Ardizzoni A. Brca Status, Molecular Profile and Clinical Variables in Primary Bilateral Breast Cancers: A Population-Based Cancer Registry Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33079-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
94
|
La Monica S, Alfieri R, Bonelli M, Cavazzoni A, Fumarola C, Galetti M, Galvani E, Ardizzoni A, Tiseo M, Petronini P. 347 Evaluation of Gefitinib Maintenance in an EGFR-mutant NSCL Cell Line With Acquired Resistance. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71037-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
95
|
Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters GJ. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2012; 23:670-677. [PMID: 21652582 DOI: 10.1093/annonc/mdr280] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A>C and 435C>T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancer patients treated with gemcitabine-platinum-regimens. PATIENTS AND METHODS CDA polymorphisms and activity were analysed by PCR and high-performance liquid chromatography, respectively. Univariate and multivariate analyses compared biological/clinical parameters with response, clinical benefit, time to progression (TtP) and overall survival (OS) using Pearson's χ(2) test, log-rank test and Cox proportional hazards model. RESULTS Patients with CDA A79A/A79C genotypes had significantly longer TtP (6.0 versus 3.0 months; P = 0.001) and OS (11.0 versus 5.0 months; P = 0.001) than patients with C79C genotype. Patients harbouring CDA C435C/C435T genotypes also had a longer OS (P = 0.025), but no correlations were observed with TtP. Conversely, patients with low-CDA activity had a significantly higher response rate (37.7% versus 13.8%; P = 0.006), clinical benefit (91.8% versus 51.7%; P < 0.001), as well as longer TtP (8.0 versus 3.0 months; P < 0.001) and OS (19.0 versus 6.0 months; P < 0.001). Furthermore, enzymatic activity emerged as an independent predictor for death/progression risk at multivariate analysis. CONCLUSIONS CDA enzymatic activity appears to be the strongest candidate biomarker of activity and efficacy of platinum-gemcitabine-based chemotherapy and should be validated in a prospective study.
Collapse
|
96
|
Carmi C, Lodola A, Rivara S, Vacondio F, Cavazzoni A, R. Alfieri R, Ardizzoni A, G. Petronini P, Mor M. Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini Rev Med Chem 2011; 11:1019-30. [DOI: 10.2174/138955711797247725] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 07/27/2011] [Accepted: 08/05/2011] [Indexed: 11/22/2022]
|
97
|
Bozzetti C, Negri FV, Naldi N, Nizzoli R, Bortesi B, Zobbi V, Azzoni C, Silini EM, Ardizzoni A. Reliability of K-ras mutational analysis on cytological samples from metastatic colorectal cancer. Pathologica 2011; 103:77-78. [PMID: 22007571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
|
98
|
Normanno N, Pinto C, Taddei GL, Mari E, Troncone G, Graziano P, Mottolese M, Ludovini V, Zupo S, De Maglio G, Russo A, Larocca LM, Di Maio M, Gambacorta M, Nappi O, Viale G, Ardizzoni A, Crinò L, Perrone F, Marchetti A. EGFR FASTnet: The Italian network for epidermal growth factor receptors (EGFR) mutation analysis in non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
99
|
Ardizzoni A, Boni L, Tiseo M, Vincent A, Passalacqua R, Camerini A, Labianca R, Genestreti G, Zanelli F, Ciuffreda L, Di Costanzo F, De Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Smit EF. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
100
|
Pressiani T, Rimassa L, Boni C, Labianca R, Fagiuoli S, Ardizzoni A, Foa P, Cortesi E, Porta C, Artioli F, Latini L, Carnaghi C, Lutman RF, Torzilli G, Tommasini M, Ceriani R, Covini G, Giordano L, Locopo N, Santoro A. Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4115] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|